



## List of content of the PPRI Report

### **PPRI Secretariat**

Gesundheit Österreich GmbH, Geschäftsbereich Österreichisches Bundesinstitut für Gesundheitswesen / Austrian Health Institute (GÖG/ÖBIG)

Stubenring 6, 1010 Vienna, Austria

E-Mail: [ppri@goeg.at](mailto:ppri@goeg.at)

Dr. Sabine Vogler, PPRI Project Manager, E-Mail: [vogler@goeg.at](mailto:vogler@goeg.at)

Mag. Claudia Habl, Deputy Project Manager, E-mail: [habl@goeg.at](mailto:habl@goeg.at)

Mag. Christine Leopold, MSc., PPRI Communication Officer, E-Mail: [leopold@goeg.at](mailto:leopold@goeg.at)

Romana Landauer, PPRI Assistant, E-Mail: [landauer@goeg.at](mailto:landauer@goeg.at)

Tel.: + 43-1-51561/262 (Ms. Landauer)

Fax.: +43 1 5138472

URL: <http://ppri.oebig.at>

# List of contents

- Abstract..... IX
- Executive Summary..... XI
- Acknowledgments .....XXIII
- List of tables ..... XXVIII
- List of figures ..... XXX
- List of boxes ..... XXXII
- List of abbreviations..... XXXIII
- List of countries .....XXXVI
- List of currencies .....XXXVII
- 1 Introduction..... 1
  - 1.1 PPRI objectives and rationale ..... 1
  - 1.2 Structure of the PPRI Report .....3
  - 1.3 Terms and definitions.....4
- 2 PPRI project .....5
  - 2.1 PPRI network .....5
    - 2.1.1 Methodology .....5
    - 2.1.2 Results .....6
    - 2.1.3 Excursus: Evaluation ..... 10
  - 2.2 PPRI dissemination..... 11
    - 2.2.1 Methodology ..... 11
    - 2.2.2 Results ..... 12
  - 2.3 PPRI needs assessment..... 13
    - 2.3.1 Methodology ..... 13
    - 2.3.2 Results ..... 14
  - 2.4 PPRI Pharma Profiles ..... 15
    - 2.4.1 Methodology ..... 15
    - 2.4.2 Results ..... 17
  - 2.5 PPRI indicators ..... 19
    - 2.5.1 Methodology ..... 19
    - 2.5.2 Results ..... 20
  - 2.6 PPRI comparative analysis ..... 20
    - 2.6.1 Methodology ..... 21
    - 2.6.2 Results ..... 21

3	Comparative analysis .....	24
3.1	Background .....	24
3.1.1	Demography .....	24
3.1.2	Economic background .....	27
3.1.3	Health care system .....	29
3.1.3.1	Organisation .....	29
3.1.3.2	Funding .....	32
3.2	Pharmaceutical system .....	35
3.2.1	Organisation.....	35
3.2.1.1	Authorities .....	35
3.2.1.2	Policy and legislation.....	40
3.2.2	Availability of pharmaceuticals.....	45
3.2.3	Market players .....	47
3.2.4	Funding.....	52
3.2.4.1	Pharmaceutical expenditure.....	52
3.2.4.2	Health expenditure and pharmaceutical expenditure.....	52
3.2.4.3	Public and private pharmaceutical expenditure .....	57
3.3	Pricing .....	58
3.3.1	Organisation.....	58
3.3.2	Pricing policies.....	58
3.3.3	Pricing procedures.....	67
3.3.4	Margins and taxes .....	72
3.3.5	Pricing related cost-containment measures .....	77
3.4	Reimbursement.....	78
3.4.1	Organisation.....	78
3.4.2	Reimbursement eligibility.....	79
3.4.2.1	Product-specific eligibility .....	79
3.4.2.2	Disease-specific eligibility .....	81
3.4.2.3	Population-group-specific eligibility .....	81
3.4.2.4	Consumption-based eligibility .....	82
3.4.3	Reimbursement lists and rates .....	83
3.4.4	Reference price systems .....	87
3.4.5	Private pharmaceutical expenses.....	90
3.4.6	Reimbursement in the hospital sector .....	96
3.4.7	Reimbursement related cost-containment measures.....	96
3.5	Rational use of pharmaceuticals.....	99
3.5.1	Pharmaceutical budgets and prescription guidelines .....	99
3.5.2	Pharmaco-economics .....	102
3.5.3	Information to patients .....	104
3.5.4	Generics.....	105
3.5.5	Consumption monitoring.....	109
4	Lessons learned .....	120
4.1	Evaluation of the PPRI project .....	120
4.2	Overview on pharmaceutical pricing and reimbursement in Europe .....	123
4.2.1	Pricing .....	123
4.2.2	Reimbursement .....	125

4.2.3	Rational use of pharmaceuticals .....	126
4.2.4	Pharmaceutical expenditure .....	126
4.3	Key findings of the PPRI analysis .....	127
4.3.1	Investment in health and pharmaceuticals .....	127
4.3.2	Pharmaceutical expenditure components .....	129
4.3.3	Growth of pharmaceutical expenditure by payers .....	130
4.3.4	Cost-containment and rational use of pharmaceuticals .....	132
4.4	Conclusions.....	134
Bibliography.....		139
Annex I: PPRI Pharma Profiles .....		
Annex II: PPRI Tools and Reports .....		

## List of tables

Table I:	PPRI Executive Summary – Set of core PPRI indicators and results .....	XIII
Table II:	PPRI Executive Summary – Pharmaceutical pricing in the outpatient sector in the PPRI countries, 2006/2007 .....	XVI
Table III:	PPRI Executive Summary – Pharmaceutical reimbursement in the outpatient sector in the PPRI countries, 2006/2007 .....	XIX
Table 2.1:	PPRI project – Participants of the PPRI network, as of October 2007 .....	7
Table 2.2:	PPRI project – Most frequently mentioned information needs regarding pharmaceutical systems .....	15
Table 2.3:	PPRI project – PPRI indicators .....	20
Table 2.4:	PPRI project – Summary .....	22
Table 3.1:	Comparative analysis – Health care systems in the PPRI countries, 2006/2007 .....	29
Table 3.2:	Comparative analysis – Number of outpatient doctors and acute care beds per 1,000 inhabitants in the PPRI countries, 2005 or latest available year .....	31
Table 3.3:	Comparative analysis – Authorities in the regulatory framework of the pharmaceutical system in the PPRI countries, 2006/2007 .....	37
Table 3.4:	Comparative analysis – Regulatory framework of pricing and reimbursement in the PPRI countries, 2006/2007 .....	41
Table 3.5:	Comparative analysis – Number of pharmaceuticals in the PPRI countries, as of 1 January 2006 or latest available year .....	45
Table 3.6:	Comparative analysis – Pharmaceutical industry and distribution in the PPRI countries, 2007 or latest available year .....	48
Table 3.7:	Comparative analysis – Price control for pharmaceuticals in the outpatient sector in the PPRI countries, 2006/2007 .....	61
Table 3.8:	Comparative analysis – Pricing policies for specific types of pharmaceuticals in the PPRI countries, 2006/2007 .....	64
Table 3.9:	Comparative analysis – Common pricing procedures for pharmaceuticals in the outpatient sector in the PPRI countries, 2006/2007 .....	68
Table 3.10:	Comparative analysis – External price referencing in the PPRI countries, 2006/2007 .....	71
Table 3.11:	Comparative analysis – Pricing policies at distribution level in the outpatient sector in the PPRI countries, 2006/2007 .....	73
Table 3.12:	Comparative analysis – Eligibility for reimbursement in the PPRI countries, 2006/2007 .....	79
Table 3.13:	Comparative analysis – Reimbursement lists and reimbursement rates in the outpatient sector in the PPRI countries, 2006/2007 .....	86
Table 3.14:	Comparative analysis – Reference price systems in the PPRI countries, 2006/2007 .....	88

Table 3.15:	Comparative analysis – Out-of pocket payments for pharmaceuticals and mechanisms for vulnerable groups in the outpatient sector in the PPRI countries, 2006/2007 .....	93
Table 3.16:	Comparative analysis – Tools for rational use of pharmaceuticals addressing physicians in the PPRI countries, 2006/2007 .....	99
Table 3.17:	Comparative analysis – Tools for generic promotion in the PPRI countries, 2006/2007 .....	107
Table 3.18:	Comparative analysis – Reference price systems and generic substitution in the PPRI countries, 2006/2007 .....	109
Table 3.19:	Comparative analysis – Consumption monitoring in the PPRI countries, 2006/2007 .....	109
Table 3.20:	Comparative analysis – PPRI at a Glance: Results of the comparative analysis per core PPRI indicator, 2006/2007 .....	114
Table 4.1:	Lessons learned – Pharmaceutical policies in five selected PPRI countries, 2007 ..	132

## List of figures

Figure 2.1:	PPRI project – The PPRI group at the fifth PPRI Coordination Meeting in Vienna, June 2007 .....	10
Figure 2.2:	PPRI project – Logo.....	12
Figure 2.3:	PPRI project – Sample of a flowchart in the PPRI Pharma Profiles, example Finland.....	18
Figure 3.1:	Comparative analysis – Population age structure 0–14, 15–64, > 64 years in percent of total population in the PPRI countries, 2005 or latest available year .....	25
Figure 3.2:	Comparative analysis – Life expectancy in the PPRI countries, 2005 or latest available year.....	26
Figure 3.3:	Comparative analysis – Gross domestic product per capita in € PPPa in the PPRI countries, 2005.....	28
Figure 3.4:	Comparative analysis – Total health expenditure per inhabitant in € PPPa in the PPRI countries, 2004.....	33
Figure 3.5:	Comparative analysis – Share of public / private funding of health expenditure in the PPRI countries, 2005 or latest available year.....	34
Figure 3.6:	Comparative analysis – Inhabitants per community pharmacy and per prescription-only medicines (POM) dispensary in the PPRI countries, 2005.....	51
Figure 3.7:	Comparative analysis – Total pharmaceutical expenditure per inhabitant in € PPPa in the PPRI countries, 2005.....	53
Figure 3.8:	Comparative analysis – Growth in pharmaceutical expenditure in the PPRI countries, 1995–2005 and 2000–2005.....	54
Figure 3.9:	Comparative analysis – Share of pharmaceutical expenditure as percentage of total health expenditure in the PPRI countries, 2005 or latest available year .....	55
Figure 3.10:	Comparative analysis – Share of public / private funding of total pharmaceutical expenditure in the PPRI countries, 2004/2005 .....	56
Figure 3.11:	Comparative analysis – Development of the shares of private pharmaceutical expenditure in the PPRI countries, 1995–2004 .....	57
Figure 3.12:	Comparative analysis – VAT rates for pharmaceuticals in the PPRI countries compared to the standard VAT, 2007.....	76
Figure 3.13:	Comparative analysis – Generics shares in volume in the outpatient sector in the PPRI countries, 2005 .....	105
Figure 3.14:	Comparative analysis – Generics shares in value in the outpatient sector in the PPRI countries, 2005.....	106
Figure 3.15:	Comparative analysis – Number of prescriptions per inhabitant in the outpatient sector in the PPRI countries, 2000 and 2006 .....	111
Figure 3.16:	Comparative analysis – Expenditure per prescription in € in the PPRI countries, 2000 and 2006.....	112

Figure 3.17: Comparative analysis – Cumulative growth in pharmaceutical expenditure and in prescriptions in volume in the PPRI countries, 2000–2005 ..... 113

Figure 4.1: Lessons learned – Share of total pharmaceutical expenditure as percentage of total health expenditure in relation to GDP per inhabitant in the PPRI countries, 2005 ..... 128

Figure 4.2: Lessons learned – Pharmaceutical expenditure per inhabitant in relation to the number of prescriptions per inhabitant in the PPRI countries, 2005 ..... 129

Figure 4.3: Lessons learned – Growth in total, public and private pharmaceutical expenditure in the PPRI countries, 2000–2004 ..... 131



## List of boxes

Box 1:	Cyprus – Two distinct health care segments (public and private sector) .....	30
Box 2:	The role of Medicines Agencies.....	36
Box 3:	Ireland – No statutory framework for pharmaceutical pricing and reimbursement.....	40
Box 4:	Canada – Fourteen pharmaceutical systems .....	44
Box 5:	Pharmaceutical Price Regulation Scheme (PPRS) – Indirect price control in the UK.....	60
Box 6:	Mechanisms of generics pricing – Examples from Austria and Estonia .....	63
Box 7:	Step-price system in Norway .....	67
Box 8:	External price referencing in Portugal.....	70
Box 9:	Price competition for the “agreed prices” in Slovakia .....	71
Box 10:	Fee-for-service remuneration for pharmacies in Slovenia.....	74
Box 11:	Pharmacy taxes .....	75
Box 12:	Discounts in Germany.....	78
Box 13:	Ireland – A mix of different reimbursement schemes .....	81
Box 14:	Consumption-based reimbursement in Denmark and Sweden .....	83
Box 15:	Positive lists in Lithuania .....	84
Box 16:	The “Festbetragssystem” / reference price system in Germany.....	90
Box 17:	Out-of pocket payment model in Estonia.....	92
Box 18:	Claw-back system in the Netherlands .....	98
Box 19:	Systematic prescription monitoring in Belgium .....	101
Box 20:	France – Social Insurance representatives visit prescribing physicians.....	102
Box 21:	The Baltic Guideline on Economic Evaluation of Pharmaceuticals .....	103
Box 22:	Cost-effectiveness assessment by NICE in the UK.....	104